



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Brief communication

Antimicrobial resistance and plasmid replicons in *Yersinia enterocolitica* strains isolated in Brazil in 30 years



Miliane R. Frazão[◇], Leonardo N. Andrade[◇], Ana L.C. Darini, Juliana P. Falcão*

Universidade de São Paulo (USP), Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Departamento de Análises Clínicas, Toxicológicas e Bromatológicas (DACTB), Ribeirão Preto, SP, Brazil

ARTICLE INFO

Article history:

Received 21 December 2016

Accepted 17 April 2017

Available online 27 May 2017

Keywords:

Yersinia enterocolitica

Resistance profile

Plasmid replicon

ABSTRACT

Some studies evaluated the resistance profile of the *Y. enterocolitica* strains isolated in diverse countries. However, in Brazil the isolation and the study of *Y. enterocolitica* are not common and therefore information about the antimicrobial resistance profile of this species in this country is scarce. Therefore, the aim of this study was to evaluate the antimicrobial resistance of *Y. enterocolitica* of biotypes 1A, 2 and 4 isolated from clinical and non-clinical sources between 1979 and 2012, in Brazil. This study showed that some *Yersinia enterocolitica* of different biotypes remain susceptible to antimicrobials used for gastroenteritis treatment. Moreover, neither acquired resistance genes nor diversity of plasmids replicons were found; however, variation in the *in vitro* intrinsic resistant pattern was detected, except the non-resistance to cefoxitin in all strains. Notwithstanding, due to epidemiological link between *Y. enterocolitica* and the pork production chain, monitoring plasmid acquired resistance in *Y. enterocolitica* could also be considered for antimicrobial resistance control purposes and food safety measures.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Yersinia enterocolitica is the most prevalent *Yersinia* species that causes illness in humans and animals. *Y. enterocolitica* strains can be classified into six biotypes, being biotypes 1B, 2, 3, 4, and 5 associated with illness in humans and animals, while biotype 1A comprises strains that are considered to be primarily nonpathogenic.¹

Y. enterocolitica intrinsic resistance to ampicillin, ticarcillin, amoxicillin-clavulanate, ceftazidime, and cephalothin has been assigned by the Clinical & Laboratory Standards Institute (CLSI).² In addition, intrinsic resistance to cefamandole and

cefoxitin has also been recognized by EUCAST.³ *Y. enterocolitica* have shown susceptibility *in vitro* to aminoglycosides, tetracycline, chloramphenicol, extended-spectrum cephalosporins, and trimethoprim-sulfamethoxazole. Resistance to fluoroquinolones has been observed in some countries due to chromosomal mutation mechanism.⁴ In Brazil, the isolation and the study of *Y. enterocolitica* are not common and thus information about the antimicrobial resistance of isolates of this species in this country is scarce.^{5–8}

Therefore, the aims of this study were to determine the antimicrobial susceptibility profile and assess the intrinsic resistance pattern, to search for plasmid acquired resistance genes, and to investigate plasmid replicons in *Y. enterocolitica* isolated in Brazil.

* Corresponding author.

E-mail address: jufalcao@fcrfp.usp.br (J.P. Falcão).

[◇] These authors contributed equally to this work.

<http://dx.doi.org/10.1016/j.bjid.2017.04.006>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

A total of 34 *Y. enterocolitica* strains biotype 1A ($n=2$), 2 ($n=12$), and 4 ($n=20$) were studied. These strains were selected from the collection of the "Brazilian Reference Center on *Yersinia* spp. other than *Y. pestis*" isolated from 1979 to 2012, based on the resistance profiles found for some other strains of the biotypes mentioned above in previous studies of our group.⁵⁻⁷

The antimicrobial susceptibility profile was determined using the disk diffusion method and interpreted according to the breakpoints for *Enterobacteriaceae*.^{2,3,9} Moreover, double-disk synergy test (DDST) was performed to detect extended-spectrum beta-lactamase (ESBL) production,¹⁰ enzymes able to hydrolyze third- and fourth-generation cephalosporins.

Plasmid acquired genes coding for resistance to extended-spectrum cephalosporins (*bla*_{CTX-M}, *bla*_{TEM} and *bla*_{SVH}), tetracyclines (*tet*), aminoglycosydes (*aac*(6')-Ib), and

fluoroquinolones (*qnr*, *aac*(6')-Ib-cr, *qepA* and *oqxAB*) were searched.¹¹⁻¹⁴ Moreover, plasmids were searched following the PCR-based replicon typing (PBRT) scheme targeting replicons of the major incompatibility groups (Inc) harboring/disseminating antibiotic resistance genes in *Enterobacteriaceae*.¹⁵

Y. enterocolitica samples showed recognized intrinsic resistance to cefazolin (CFZ) (34/34), cephalotin (CF) (34/34), ampicillin (AMP) and ticarcillin (TIC) (32/34), and amoxicillin-clavulanic acid (AMC) (19/34). This inherent non-susceptibility pattern has been displayed by all or almost all strains from different biotypes and isolation sources. However, cefoxitin (FOX) intrinsic resistance, additionally also recognized by EUCAST,¹⁶ was not detected (Table 1).

Most *Y. enterocolitica* isolates harbored chromosomal genes *bla*_A and *bla*_B encoding for two beta-lactamases, respectively,

Table 1 – General data of the 34 *Yersinia enterocolitica* strains studied.

Strains	Biotype	Source	Year	Resistance profile
IP 7382 ^a	4	Animal feces	1979	AMP, TIC, CFZ, CF, <u>NIT</u>
IP 7884 ^a	4	Animal feces	1979	AMP, TIC, CFZ, CF
FCF 57	1A	Milk	1980	AMP, TIC, AMC, CFZ, CF, <u>NIT</u>
FCF 86	2	Fresh water	1982	AMP, TIC, AMC, CFZ, CF
FCF 88	2	Fresh water	1983	AMP, TIC, AMC, CFZ, CF
FCF 268	1A	Chicken meat	1984	AMP, TIC, AMC, CFZ, CF
FCF 90	2	Fresh water	1984	AMP, TIC, AMC, CFZ, CF
FCF 376 ^a	4	Human feces	1984	AMP, TIC, CFZ, CF
FCF 93	2	Fresh water	1985	AMP, TIC, AMC, CFZ, CF
FCF 94	2	Fresh water	1986	AMP, TIC, CFZ, CF
FCF 96	2	Fresh water	1987	AMP, TIC, CFZ, CF
FCF 100	2	Fresh water	1988	AMP, TIC, AMC, CFZ, CF, <u>PTZ</u>
FCF 418 ^a	4	Human diarrheic feces	1988	AMP, TIC, CFZ, CF
FCF 103	2	Fresh water	1989	AMP, TIC, CFZ, CF
FCF 105	2	Fresh water	1990	AMP, TIC, CFZ, CF
FCF 110	2	Fresh water	1991	AMP, TIC, AMC, CFZ, CF
FCF 113	2	Fresh water	1992	AMP, TIC, CFZ, CF
FCF 115	2	Fresh water	1993	AMC, CFZ, CF
FCF 600 ^a	4	Human diarrheic feces	1998	AMP, TIC, CFZ, CF, <u>CPM</u>
FCF 601	4	Animal feces	1998	AMP, TIC, AMC, CFZ, CF
FCF 605 ^a	4	Human diarrheic feces	1999	AMP, TIC, CFZ, CF, <u>NIT</u>
FCF 606 ^a	4	Human diarrheic feces	1999	AMP, TIC, AMC, CFZ, CF, <u>NAL</u> , <u>NIT</u>
FCF 607 ^a	4	Human diarrheic feces	1999	AMP, TIC, AMC, CFZ, CF, <u>CPM</u> , <u>NIT</u>
FCF 609 ^a	4	Human diarrheic feces	2000	AMP, TIC, CFZ, CF, <u>NAL</u>
FCF 612 ^a	4	Human diarrheic feces	2000	AMP, TIC, AMC, CFZ, CF
FCF 613 ^a	4	Human diarrheic feces	2003	AMP, TIC, CFZ, CF, <u>NAL</u>
FCF 614 ^a	4	Human diarrheic feces	2003	AMP, TIC, CFZ, CF, <u>NAL</u> , <u>SXT</u>
FCF 615 ^a	4	Human blood	2004	AMP, TIC, AMC, CFZ, CF
FCF 618 ^a	4	Human diarrheic feces	2008	AMP, TIC, CFZ, CF, <u>NAL</u> , <u>KAN</u>
FCF 619 ^a	4	Human diarrheic feces	2008	AMP, TIC, AMC, CFZ, CF, <u>SXT</u>
FCF 620 ^a	4	Human blood	2008	AMC, CFZ, CF
FCF 624 ^a	4	Lymph node swab	2010	AMP, TIC, AMC, CFZ, CF, <u>CFX</u> , <u>NAL</u> , <u>NOR</u> , <u>CIP</u> , <u>LEV</u> , <u>TET</u> , <u>DOX</u> , <u>SXT</u> , <u>NIT</u> , <u>FOS</u>
FCF 625 ^a	4	Lymph node swab	2010	AMP, TIC, CFZ, CF
FCF 626 ^a	4	Human blood	2012	AMP, TIC, AMC, CFZ, CF, <u>NAL</u>

Bold and underline type means acquired resistance other than plasmid acquired resistance investigated here.

AMP, ampicillin; TIC, ticarcillin; AMC, amoxicillin-clavulanic acid; PTZ, piperacillin-tazobactam; CF, cephalotin; CFZ, cefazolin; CFX, cefuroxime; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CPM, cefepime; ATM, aztreonam; ERT, ertapenem; GEN, gentamicin; AMI, amikacin; KAN, kanamycin; SXT, trimethoprim-sulfamethoxazole; NAL, nalidixic acid; NOR, norfloxacin; CIP, ciprofloxacin; LEV, levofloxacin; C, chloramphenicol; NIT, nitrofurantoin; TET, tetracycline; DOX, doxycyclin; TGC, tigecycline; PB, polymyxin B; FOS, fosfomicin. All manufactured by Oxoid (Basingstoke, Hampshire, UK).

^a Presence of IncFII_γ plasmid replicon.

BlaA (a non-inducible broad-spectrum carbenicillinase) and BlaB (an AmpC-type inducible cephalosporinase).¹⁷ The differential expression and activities of these two enzymes determine the differential beta-lactam intrinsic resistance among biotypes of *Y. enterocolitica*.⁴ Moreover, a small percentage of strains may appear susceptible due to laboratory method variation, mutation or resistance expression. Therefore, *in vitro* susceptible results should be viewed with caution because *in vivo* non-susceptibility could lead to therapeutic failure. Approximately half of the strains (14/34) showed also acquired resistance (Table 1). Beta-lactam resistance to piperacillin-tazobactam (PTZ) and cefuroxime (CFX) could have been due to BlaB (AmpC) overproduction. However, BlaB overproduction does not explain cefepime (CPM) resistance, once AmpC beta-lactamases are not able to hydrolyze fourth-generation cephalosporins (like CPM). Thereby, once ESBL production was not detected and the recognized enzymatic intrinsic resistance is not able to confer this phenotype, other mechanism of resistance like porin loss and/or over expression of efflux system could have been responsible to CPM as well as PTZ and CFX resistance in the isolates studied here.^{17,18} Nitrofurantoin (NIT) resistance was detected in 17.6% (6/34) of strains; other studies reported 36% resistant¹⁹ as well as 100% susceptible strains.²⁰ Trimethoprim-sulfamethoxazole (SXT) resistance was founded in 8.8% (3/34) of strains, and 4%²⁰ to 10%²¹ of resistance were seen in other studies. Nalidixic acid (NAL) resistance was observed in 20.5% (7/34) of strains and other studies have described an increasing number of strains showing NAL resistance over recent years²² reaching 23%.²³ In addition, fluoroquinolones like norfloxacin (NOR), ciprofloxacin (CIP), and levofloxacin (LEV) resistance was found in just one strain named FCF624, corroborating the findings of other studies where rates of fluoroquinolone resistance were significantly lower than those observed for NAL alone.²² Tetracycline (TET), doxycycline (DOX), kanamycin (KAN), and fosfomicin (FOS) resistance were also detected in the FCF624 strain (Table 1), showing multiple resistance phenotypes, rarely reported in *Y. enterocolitica*.⁴

No plasmid acquired genes coding for resistance to extended-spectrum cephalosporins, tetracyclines, aminoglycosides, and fluoroquinolones were found. Thereby, resistance to these antimicrobial classes could have chromosomal origin.

In this study, just IncFII γ plasmid replicon were detected mostly in strains of the pathogenic biotype 4 isolated from human diarrheic feces; however, it did not relate to any acquired resistance genes (Table 1). IncFII-like plasmids are mostly considered as virulence plasmids, such as pYV harboring type III secretion system (*yops*), that can be present alone or co-resident and compatible with other FII-positive resistance plasmids (typable by the FII, FIA, FIB, FIC loci) within the same bacterial cell²⁴ (<http://pubmlst.org/plasmid/>). Plasmids carrying transferable antibiotic resistance genes have been detected from a variety of *Enterobacteriaceae*²⁵; however reports in *Y. enterocolitica* are rare,⁴ such as the conjugative plasmid (30–40 kb) transferring chloramphenicol, streptomycin, and sulfonamide resistance phenotypes from a sporadic *Y. enterocolitica* 4/O:3 strain.²⁶

Y. enterocolitica is a non-hospital pathogen and the absence of acquired resistance genes could be explained by

little interaction with hospital pathogens and consequently a reduced possibility to genetic exchanges, such as horizontal gene transfer mediated by plasmids. Nevertheless, resistance genes and resistant bacteria have been alarmingly and increasingly found in food and food-producing animals,²⁷ such as *mcr-1* gene in ESBL-producing *Escherichia coli* strains isolated from pig.²⁸ *Y. enterocolitica* is a zoonotic pathogen that causes gastrointestinal disease and porcine animal seems to be the main carrier of this bacterial species.²⁹ Likewise, the food chain could boost *Y. enterocolitica* antimicrobial resistance.

In summary, our study showed that some Brazilian *Y. enterocolitica* strains of different biotypes remain susceptible to drugs used for treating gastroenteritis, as well as extra-intestinal and hospital infections. In addition, variation in the *in vitro* intrinsic resistant pattern was detected, except non-resistance to FOX in all strains. Moreover, neither acquired resistance genes nor diversity of plasmids replicons searched were found. Notwithstanding, due to epidemiological link between *Y. enterocolitica* and pork production chain, monitoring plasmid acquired resistance in *Y. enterocolitica* could also be considered for antimicrobial resistance control purposes and food safety measures.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

We thank Sao Paulo Research Foundation (FAPESP-2012/19132-1) for financial support. During the course of this work, Frazão, M.R. was supported by a scholarship granted by Coordination for the Improvement of the Higher Education Personnel (CAPES). Andrade, L.N. was supported by a postdoctoral fellowship from Programa Nacional de Pós Doutorado (PNPD)/CAPES 2015.

REFERENCES

1. Drummond N, Murphy BP, Ringwood T, Prentice MB, Buckley JE, Fanning S. *Yersinia enterocolitica*: a brief review of the issues relating to the zoonotic pathogen, public health challenges, and the pork production chain. *Foodborne Pathog Dis*. 2012;9:179–89. Epub 2012/01/06.
2. CLSI. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. Clinical Lab Standards Institute; 2016. M100S (26th edition).
3. EUCAST ECoAST. Breakpoint tables for interpretation of MICs and zone diameters 2016; Version 6.0, valid from 2016-01-01.
4. Fabrega A, Vila J. *Yersinia enterocolitica*: pathogenesis, virulence and antimicrobial resistance. *Enferm Infecc Microbiol Clin*. 2012;30:24–32. Epub 2011/10/25.
5. Falcao JP, Brocchi M, Proenca-Modena JL, Acrani GO, Correa EF, Falcao DP. Virulence characteristics and epidemiology of *Yersinia enterocolitica* and *Yersinia* other than *Y. pseudotuberculosis* and *Y. pestis* isolated from water and sewage. *J Appl Microbiol*. 2004;96:1230–6. Epub 2004/05/14.
6. Falcao JP, Falcao DP, Pitondo-Silva A, Malaspina AC, Brocchi M. Molecular typing and virulence markers of *Yersinia enterocolitica* strains from human, animal and food origins

- isolated between 1968 and 2000 in Brazil. *J Med Microbiol*. 2006;55 Pt 11:1539–48. Epub 2006/10/13.
7. Campioni F, Falcao JP. Genotypic diversity and virulence markers of *Yersinia enterocolitica* biotype 1A strains isolated from clinical and non-clinical origins. *APMIS*. 2014;122:215–22. Epub 2013/06/15.
 8. Frazao MR, Falcao JP. Genotypic diversity and pathogenic potential of *Yersinia enterocolitica* biotype 2 strains isolated in Brazil. *J Appl Microbiol*. 2015;118:1058–67. Epub 2015/02/03.
 9. CLSI CaLSI. Performance standards for antimicrobial disk susceptibility tests. Clinical and Laboratory Standards Institute; 2016. M02-A12 (12th edition).
 10. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. *Rev Infect Dis*. 1988;10:867–78. Epub 1988/07/01.
 11. Andrade LN, Minarini LA, Pitondo-Silva A, et al. Determinants of beta-lactam resistance in meningitis-causing Enterobacteriaceae in Brazil. *Can J Microbiol*. 2010;56:399–407.
 12. Tamang MD, Nam HM, Chae MH, et al. Prevalence of plasmid-mediated quinolone resistance determinants among *Escherichia coli* isolated from food animals in Korea. *Foodborne Pathog Dis*. 2012;9:1057–63.
 13. Kim HB, Wang M, Park CH, Kim EC, Jacoby GA, Hooper DC. *oqxAB* encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. *Antimicrob Agents Chemother*. 2009;53:3582–4. Epub 2009/06/17.
 14. Ng LK, Martin I, Alfa M, Mulvey M. Multiplex PCR for the detection of tetracycline resistant genes. *Mol Cell Probes*. 2001;15:209–15. Epub 2001/08/22.
 15. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods*. 2005;63:219–28.
 16. Bent ZW, Young GM. Contribution of *BlaA* and *BlaB* beta-lactamases to antibiotic susceptibility of *Yersinia enterocolitica* biovar 1B. *Antimicrob Agents Chemother*. 2010;54:4000–2. Epub 2010/06/16.
 17. Liu C, Wang X, Chen Y, et al. Three *Yersinia enterocolitica* AmpD homologs participate in the multi-step regulation of chromosomal cephalosporinase AmpC. *Front Microbiol*. 2016;7:1282. Epub 2016/09/03.
 18. Jacoby GA. AmpC beta-lactamases. *Clin Microbiol Rev*. 2009;22:161–82.
 19. Gousia P, Economou V, Sakkas H, Leveidiotou S, Papadopoulou C. Antimicrobial resistance of major foodborne pathogens from major meat products. *Foodborne Pathog Dis*. 2011;8:27–38. Epub 2010/11/03.
 20. Funk JA, Troutt HF, Davis SA, Fossler CP. In vitro susceptibility of *Yersinia enterocolitica* isolated from the oral cavity of swine. *J Food Prot*. 2000;63:395–9. Epub 2000/03/15.
 21. Rusak LA, dos Reis CMF, Barbosa AV, et al. Phenotypic and genotypic analysis of bio-serotypes of *Yersinia enterocolitica* from various sources in Brazil. *J Infect Dev Countries*. 2014;8:1533–40.
 22. Fabrega A, Roca I, Vila J. Fluoroquinolone and multidrug resistance phenotypes associated with the overexpression of *AcrAB* and an orthologue of *MarA* in *Yersinia enterocolitica*. *Int J Med Microbiol*. 2010;300:457–63. Epub 2010/06/01.
 23. Capilla S, Ruiz J, Goni P, et al. Characterization of the molecular mechanisms of quinolone resistance in *Yersinia enterocolitica* O:3 clinical isolates. *J Antimicrob Chemother*. 2004;53:1068–71. Epub 2004/05/01.
 24. Villa L, Garcia-Fernandez A, Fortini D, Carattoli A. Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. *J Antimicrob Chemother*. 2010;65:2518–29. Epub 2010/10/12.
 25. Carattoli A. Resistance plasmid families in Enterobacteriaceae. *Antimicrob Agents Chemother*. 2009;53:2227–38.
 26. Sihvonen LM, Toivonen S, Haukka K, Kuusi M, Skurnik M, Siitonen A. Multilocus variable-number tandem-repeat analysis, pulsed-field gel electrophoresis, and antimicrobial susceptibility patterns in discrimination of sporadic and outbreak-related strains of *Yersinia enterocolitica*. *BMC Microbiol*. 2011;11:42. Epub 2011/02/26.
 27. Liebana E, Carattoli A, Coque TM, et al. Public health risks of enterobacterial isolates producing extended-spectrum beta-lactamases or AmpC beta-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. *Clin Infect Dis*. 2013;56:1030–7.
 28. Brauer A, Telling K, Laht M, et al. Plasmid with colistin resistance gene *mcr-1* in ESBL-producing *Escherichia coli* strains isolated from pig slurry in Estonia. *Antimicrob Agents Chemother*. 2016. Epub 2016/08/31.
 29. Drummond N, Stephan R, Haughton P, Murphy BP, Fanning S. Further characterization of three *Yersinia enterocolitica* strains with a nalidixic acid-resistant phenotype isolated from humans with diarrhea. *Foodborne Pathog Dis*. 2013;10:744–6. Epub 2013/06/12.